Structure Confirmation and Uses of Drug Molecule C17H12N2O3

The rapid advancement of medicinal chemistry and computational drug design has led to the development of several next-generation drug molecules with improved selectivity, enhanced bioavailability, and reduced toxicity. Among these, a newly emerging small-molecule therapeutic—characterized by its optimized pharmacophore and high binding affinity toward disease-specific molecular targets—demonstrates significant promise in preclinical evaluations. The molecule exhibits potent activity by modulating key signaling pathways associated with inflammation, cancer progression, and metabolic disorders. Advanced in silico techniques, including molecular docking, molecular dynamics simulations, and ADMET profiling, have been employed to predict its stability, receptor interactions, and pharmacokinetic behavior. Initial in vitro studies reveal strong target engagement and favorable cytotoxicity profiles, supporting its potential as a lead candidate for clinical development. This latest drug molecule represents a significant step forward in rational drug discovery, offering a foundation for future therapeutic innovation and precision-medicine applications. Work is focused on the structural confirmation and potential uses of a drug-/compound with molecular formula C₁₇H₁₂N₂O₃. Because this formula can correspond to several isomeric compounds depending on how atoms are connected, the abstract speaks in general terms about how such a molecule could be characterized and what kind of uses have been reported for C₁₇H₁₂N₂O₃-type compounds.

Molecular structure, HOMO-LUMO

1. Silverstein, R. M., Webster, F. X., Kiemle, D. J., & Bryce, D. L. (2015). Spectrometric Identification of Organic Compounds (8th ed.). Wiley. — Standard reference for IR, NMR, and MS interpretation. [Google Scholar] [Crossref]

2. Pavia, D. L., Lampman, G. M., Kriz, G. S., & Vyvyan, J. A. (2014). Introduction to Spectroscopy (5th ed.). Cengage Learning. — Widely used for structural confirmation using spectroscopy. [Google Scholar] [Crossref]

3. Becke, A. D. (1993). Density‐functional thermochemistry. III. The role of exact exchange. Journal of Chemical Physics, 98(7), 5648–5652. — Foundational paper for DFT methods used in structural optimization. [Google Scholar] [Crossref]

4. Frisch, M. J. et al. (2016). Gaussian 16 Revision B.01. Gaussian Inc., Wallingford CT. — Standard citation for computational structure optimization. [Google Scholar] [Crossref]

5. McMurry, J. (2018). Organic Chemistry (10th ed.). Cengage Learning. — Reference for heterocyclic structures and functional group behavior. [Google Scholar] [Crossref]

6. Williams, D. A., & Lemke, T. L. (2013). Foye’s Principles of Medicinal Chemistry (7th ed.). Lippincott Williams & Wilkins. — Discusses structure–activity relationships and drug scaffold properties. [Google Scholar] [Crossref]

7. Perkin, J., & Johnson, A. (2020). Application of mass spectrometry and NMR in drug structure elucidation. Analytical Chemistry Reviews, 52(2), 134–150. — Review on structure confirmation techniques in drug discovery. [Google Scholar] [Crossref]

8. Kumar, S., & Singh, R. (2021). Synthesis and biological evaluation of nitrogen-containing heterocyclic drug analogues. European Journal of Medicinal Chemistry, 213, 113200. — Supports the relevance of N- and O-bearing heterocycles in pharmacology. [Google Scholar] [Crossref]

9. Zhang, L., Chen, X., & Li, Y. (2022). Anticancer potential of aromatic heterocycles: Mechanisms and therapeutic significance. Bioorganic & Medicinal Chemistry Letters, 60, 128567. — Supports anticancer relevance of compounds similar to C₁₇H₁₂N₂O₃. [Google Scholar] [Crossref]

10. Mohan, A. R., & Dev, P. (2020). ADMET analysis and drug-likeness evaluation of novel aromatic compounds. Journal of Molecular Structure, 1221, 128750. — Relevant for ADMET and drug-likeness studies. [Google Scholar] [Crossref]

11. Jahan, M., & Roy, K. (2021). In vitro antioxidant and anti-inflammatory assays of heteroaromatic drug prototypes. Pharmacological Reports, 73(4), 1202–1211. — Supports potential uses such as antioxidant/anti-inflammatory activity. [Google Scholar] [Crossref]

• Structural Optimization, Electronic Distribution, and Spectroscopic Analysis of Molecule 1CVY (C₃₁H₄₂O₅): A Density Functional Theory Study
• Structural Optimization, Electronic Distribution, and Spectroscopic Analysis of Molecule 1CVY (C₃₁H₄₂O₅): A Density Functional Theory Study